Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail)

Clinical Trial ID NCT00988208

PubWeight™ 14.52^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00988208

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.	Lancet Oncol	2015	2.59
2	Novel therapies for metastatic castrate-resistant prostate cancer.	J Natl Cancer Inst	2011	1.98
3	Drug resistance in metastatic castration-resistant prostate cancer.	Nat Rev Clin Oncol	2010	1.86
4	Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.	Cancer J	2013	1.09
5	Targeting angiogenesis for the treatment of prostate cancer.	Expert Opin Ther Targets	2012	0.97
6	The changing landscape in the treatment of metastatic castration-resistant prostate cancer.	Ther Adv Med Oncol	2013	0.97
7	Critical appraisal of cabazitaxel in the management of advanced prostate cancer.	Clin Interv Aging	2010	0.96
8	Angiogenesis inhibitors in the treatment of prostate cancer.	J Hematol Oncol	2010	0.91
9	Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.	J Clin Oncol	2013	0.87
10	The project data sphere initiative: accelerating cancer research by sharing data.	Oncologist	2015	0.83
11	Emerging targeted therapies for castration-resistant prostate cancer.	Front Endocrinol (Lausanne)	2012	0.81
12	Future directions in castrate-resistant prostate cancer therapy.	Clin Genitourin Cancer	2010	0.79
13	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.	Eur Urol	2016	0.77